secwatch.observer — SEC 8-K summary
======================================

Issuer:     InspireMD, Inc. (NSPR)
CIK:        0001433607
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001641172-25-009364
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InspireMD Q1 net loss widens to $0.22/sh; FDA approval of CGuard Prime expected Q3 2025
--------------------------------------------------------------------------------

- Revenue $1.529M (+1.2% YoY); net loss $11.166M ($0.22/sh) vs $7.032M loss ($0.21/sh) in Q1 2024.
- Operating expenses rose 52.5% to $11.752M on U.S. sales force build and CGuard Prime launch preparation.
- Cash and securities $26.086M at March 31, down from $34.637M at Dec 31, 2024.
- FDA PMA for CGuard Prime carotid stent system anticipated in Q3 2025; commercial team in place.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1433607/000164117225009364/0001641172-25-009364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1433607/000164117225009364/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer